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and Jung Hyun Chang, MD, PhD
Introduction: Reduced lung function is an important risk factor for
lung cancer and increases surgical risk in patients with operable
stages of lung cancer. Nevertheless, there have been few studies to
reveal association of lung function with mortality in patients with
advanced lung cancer. The aim of this study was to investigate
whether low forced expiratory volume in 1 second (FEV1) is an
independent predictor of mortality in patients with advanced lung
cancer.
Methods: Data were retrospectively collected from patients with
non-small cell lung cancer of stage IIIB or IV and available spirom-
etry at diagnosis of lung cancer. They had the last follow-up
consecutively between April 2003 and July 2009 in a tertiary referral
hospital.
Results: Among a total of 156 patients, 118 died as of July 2009.
Their mean age was 65 years; 115 (74%) were men. Mean FEV1
was 1.91 liters (79% of predicted). Seventy-one patients (46%)
had adenocarcinoma, and 48 (31%) had squamous cell carci-
noma. In a multivariate analysis using Cox regression model,
independent prognostic factors were FEV1 less than 50% of
predicted (hazard ratio [HR]  2.704, 95% confidence interval
[CI]: 1.516–4.823, p  0.001), chemotherapy (HR  0.311, 95%
CI: 0.192–0.503, p  0.001), adenocarcinoma (HR  0.459,
95% CI: 0.300–0.701, p  0.001), body mass index (HR 
0.921, 95% CI: 0.870–0.975, p  0.005), and the presence of
malignant pleural effusion (HR  1.673, 95% CI: 1.102–2.540,
p  0.016).
Conclusions: Reduced FEV1 is strongly associated with mortality in
advanced non-small cell lung cancer.
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rometry, Forced expiratory volume.
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The relationship between smoking, lung cancer, and air-flow obstruction is well recognized.1,2 Several studies
have suggested that airway obstruction, based on forced
expiratory volume in 1 second (FEV1) reduction, increases
lung cancer risk.3–5 In a large prospective cohort of heavy
smokers, even a relatively small reduction in FEV1 % pre-
dicted is a significant predictor of increased lung cancer risk.6
On the other hand, surgical resection remains the treatment of
choice for anatomically resectable non-small cell lung cancer
(NSCLC),7 offering the best prospect of long-term survival.
Nevertheless, many patients have coexisting chronic airflow
limitation and/or diffusion impairment,8 which is associated
with an increased risk from surgery.9,10 Therefore, preopera-
tive lung function test is mandatory for NSCLC surgery.
Practically, early diagnosis of lung cancer has not been
possible, and unfortunately, almost patients with lung cancer
belong to advanced stages at the time of diagnosis.
In patients with advanced NSCLC, factors essential to
decision making are the extent of disease, weight loss, and
performance status, as these are the most predictive indicators
of median patient survival time after undergoing systemic
chemotherapy.11 For patients without substantial systemic
manifestations of illness, chemotherapy is known to improve
median survival time, when compared with the best support-
ive care alone.12,13 Good performance status, female sex, age
70 years, and cisplatin-based chemotherapy have been
known to be predictive of favorable survival rates overall.14
Nevertheless, a few studies have evaluated FEV1 as a prog-
nostic factor in advanced NSCLC.
The aim of this study is to know whether FEV1 is an
independent prognostic factor in patients with advanced
NSCLC.
PATIENTS AND METHODS
We consecutively collected data from patients with
NSCLC of stage IIIB or IV and available spirometry at
diagnosis of lung cancer, who had the last follow-up between
April 2003 and July 2009 in the Ewha Womans University
Hospital. They were diagnosed with advanced NSCLC be-
tween September 21, 2000, and March 26, 2009. The staging
was decided according to the sixth edition of TNM classifi-
cation of NSCLC. Among them, we excluded those whose
survival had not been verified as of July 31, 2009. Finally,
156 patients were retrospectively reviewed, and data of age,
gender, height, weight, smoking history, comorbidities, stage
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and histology of lung cancer, history of chemotherapy and/or
radiation, and the presence or absence of malignant effusion
were collected. The institutional review board approved the
analyses of the data.
Pulmonary Function Tests
Spirometry was performed as recommended by the
American Thoracic Society using the Vmax 22 (Sensor Med-
ics, Yorba Linda, CA).15 The following values were evalu-
ated: FEV1, forced vital capacity (FVC), and the ratio of
FEV1 to FVC (FEV1/FVC).
Statistical Analysis
Statistical analysis was performed using SPSS-PC for
Windows Version 17.0 (SPSS Inc., Chicago, IL). Descriptive
data are expressed as mean  SD, and frequencies are
expressed as number (%). Differences between two groups
were tested using the Student’s t test. Categorical variables
were analyzed using 2 test. Overall survival was defined as
the interval between the date of pathologic diagnosis and
death or last follow-up with any death defined as an event.
Cumulative survival was analyzed by the Kaplan-Meier
method and compared by log-rank test. A multivariate Cox
proportional hazard model was used to identify prognostic
factors. Statistical significance was accepted at the p values of
less than 0.05 level.
RESULTS
Among 156 patients, 118 died as of July 2009. Their
mean age was 65 years; 115 (74%) were men. Survivors had
higher body mass index (BMI) than nonsurvivors (p 
0.029). Never smokers are more common in survivors (p 
0.028) (Table 1). Seventy-one patients (46%) had adenocar-
cinoma, and 48 (31%) had squamous cell carcinoma. There
were 59 at stage IIIb and 97 at stage IV (Table 2). Mean FEV1
was 1.91 liters (79% of predicted). Survivors had higher
FEV1 (p  0.006) and FEV1 % predicted compared with
nonsurvivors (p  0.028) (Table 3).
Patients with FEV1 less than 50% predicted showed
shorter median survival than those with FEV1 50% pre-
dicted (35 days versus 451 days, p  0.001) (Figure 1A).
Patients who had received chemotherapy showed longer me-
dian survival than chemotherapy-naive patients (517 days
versus 221 days, p  0.001) (Figure 1B). Patients with
adenocarcinoma had 547 days median survival compared
with 331 days for those with nonadenocarcinoma (p 0.002)
(Figure 1C). Patients with malignant effusion had shorter
median survival compared with those without effusion (275
days versus 451 days, p  0.002) (Figure 1D). The median
survival for patients with radiation therapy was 510 days
compared with 331 days for patients who had not received
radiation therapy (p  0.043) (Figure 1E). Survival was not
influenced by gender (p  0.088, Figure 1F), initial clinical
stage, and smoking history.
In a multivariate analysis using Cox regression model,
independent prognostic factors were FEV1 less than 50% of
predicted (versus FEV1 50% predicted; hazard ratio
[HR]  2.704, 95% confidence interval [CI]: 1.516–4.823,
p  0.001), chemotherapy (versus no chemotherapy; HR 
0.311, 95% CI: 0.192–0.503, p  0.001), adenocarcinoma
(versus nonadenocarcinoma; HR  0.459, 95% CI: 0.300–
0.701, p 0.001), BMI (HR 0.921, 95% CI: 0.870–0.975,
p  0.005), and the presence of malignant pleural effusion
TABLE 1. Patient Characteristics
Variables
Total
(N  156)
Survivor
(N  38)
Nonsurvivor
(N  118) p
Age (yr) 65  10 63  11 66  10 0.051
Male (%) 115 (74%) 26 (68%) 89 (75%) 0.394
Height (cm) 162  9 164  9 162  9 0.343
Weight (kg) 60  11 64  11 59  10 0.008
Body mass index (kg/m2) 23  4 24  3 22  4 0.029
Smokinga
Never smoker (%) 78 (50%) 25 (66%) 53 (45%) 0.028
Current smoker (%) 55 (36%) 7 (18%) 48 (41%) 0.011
Smoking (pack-years) 20  27 13  22 22  27 0.070
Comorbidities
Diabetes mellitus 27 (17%) 6 (16%) 21 (18%) 0.776
Hypertension 37 (24%) 8 (21%) 29 (25%) 0.197
Tuberculosis 22 (14%) 3 (8%) 19 (16%) 0.206
COPD 5 (3%) 0 (0%) 5 (4%) 0.197
Stroke 7 (5%) 2 (5%) 5 (4%) 0.790
a Data were from 155 patients.
COPD, chronic obstructive pulmonary disease.
TABLE 2. Lung Cancer-Related Characteristics
Variables
Total
(N  156)
Survivor
(N  38)
Nonsurvivor
(N  118) p
Histology
Adenocarcinoma 71 (46%) 22 (58%) 49 (42%) 0.078
Squamous cell carcinoma 48 (31%) 9 (24%) 39 (33%) 0.277
Other associated condition
Malignant effusion 43 (28%) 6 (16%) 37 (31%) 0.062
IIIB 11 (7%) 5 (13%) 6 (5%)
IV 32 (21%) 1 (3%) 31 (26%)
Chemotherapy 81 (52%) 22 (58%) 59 (50%) 0.397
Radiation therapy 40 (26%) 4 (11%) 36 (31%) 0.014
TNM stage
IIIB 59 (38%) 18 (47%) 41 (35%) 0.163
IV 97 (62%) 20 (53%) 77 (65%)
TNM, tumor node metastasis.
TABLE 3. Lung Function
Variables
Total
(N  156)
Survivor
(N  38)
Nonsurvivor
(N  118) p
FVC (L) 2.82  0.98 3.07  0.98 2.74  0.96 0.066
FVC % predicted 81  21 86  20 80  21 0.085
FEV1 (L) 1.91  0.68 2.17  0.68 1.82  0.67 0.006
FEV1 % predicted 79  23 86  20 76  23 0.028
FEV1/FVC (%) 69  12 72  12 68  13 0.071
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 sec.
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(versus no pleural effusion; HR  1.673, 95% CI: 1.102–
2.540, p  0.016) (Table 4).
DISCUSSION
Although lung function is well known to be an impor-
tant prognostic factor for patients with NSCLC to consider
surgery,9,10 the significance in advanced NSCLC has not been
properly appreciated. In this study, FEV1 less than 50%
predicted was an independent predictor of mortality for ad-
vanced NSCLC in both univariate and multivariate analyses.
Forced expiratory volume is only one measure of respiratory
function. It does have the advantage, however, of being an
objective and quantitative measure, whereas many other mea-
sures are based on self-reporting. Adjustments for age and
height for each sex can be built in to assess the relevance of
an individual level. In general population, reduced FEV1 has
been reported to be a predictor of mortality.16,17 It was second
in importance to cigarette smoking as a predictor of subse-
FIGURE 1. Kaplan–Meier survival
curves. A, Forced expiratory vol-
ume in 1 second (FEV1)  50%
predicted versus FEV1 less than
50% predicted. B, No chemother-
apy versus chemotherapy. C, Non-
adenocarcinoma versus adenocarci-
noma. D, No malignant effusion
versus malignant effusion. E, No
radiotherapy versus radiotherapy.
F, Male versus female. Tick marks
indicate censored data.
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quent all cause mortality and is as important as cholesterol in
predicting mortality from ischemic heart disease.16 Increased
mortality associated with low FEV1, with the exception of the
cancers, appeared for lifelong nonsmokers.16 Similarly, in
this study including subjects with lung cancer, a representa-
tive smoking-related cancer, never smokers showed no sta-
tistical survival benefit, whereas low FEV1 predicts short
survival. We chose FEV1 of less than 50% predicted as a
criterion of lung function decline. One of the reasons is that
clinically patients rarely feel shortness of breath during daily
activity until FEV1 is reduced to 50% of predicted. On the
other hand, even though some of our subjects had pulmonary
insufficiency of restrictive or mixed type, FEV1 less than 50%
predicted is well known as a criterion of severe airway
obstruction according to the Global initiative for Obstructive
Lung Disease guideline18 and a predictor of mortality in
patients with chronic obstructive pulmonary disease.19
Consistently with previous reports,12,13,20,21 chemother-
apy and the presence of malignant pleural effusion20,21 have
prognostic implication in advanced NSCLC. Now malignant
effusion is considered as metastasis and not as T4 in a recent
update of TNM staging system.22
In this study, patients with adenocarcinoma showed
much better survival than those with nonadenocarcinoma. It
may be due to the development of new chemotherapy such as
epidermal growth factor receptor tyrosine kinase inhibitors
and pemetrexed. Until the introduction of these agents, sur-
vival rate was not different among the histologic types of
NSCLC except bronchioloalveolar carcinoma, which repre-
sents favorable outcome.23 In surgically resected NSCLC,
several studies have shown an improved survival for squa-
mous cell histology over nonsquamous cell histology.10,24
Although squamous cell carcinoma tends to appear as a
central bronchogenic tumor, adenocarcinoma is likely to be a
peripheral cancer and early metastasis.
In this study, low BMI also predicts short survival. Low
BMI has been associated with increased risk of lung cancer
particularly in men and smoker.25,26 Recent two studies also
showed that low BMI in smokers increases mortality from
lung cancer.27,28 The association between low BMI and lung
cancer is unexplained and warrants further investigation. In
advanced lung cancer, low BMI might mean systemic con-
sequence of malignancy and/or poor nutritional status.
In contrast to the previous studies,11,14 neither age nor
gender predicts prognosis. It may be partly due to the devel-
opment of new chemotherapeutic agents, which are much
tolerable for patients with advanced NSCLC with poor per-
formance status. Recent studies of prognostic factors in
resected NSCLC showed that women survive longer than do
men.29,30 In this study including only advanced NSCLC,
although the median survival time of women was longer than
that of men, the difference did not reach statistical signifi-
cance. Also, subgroup analyses for patients with adenocarci-
noma did not revealed any differences according to gender or
smoking status. It might be due to differences in mutation
status, which was not obtained, or the other unknown possi-
bilities. Especially for new chemotherapeutic agents such as
pemetrexed and epidermal growth factor receptor tyrosine
kinase inhibitors, prognostic factors such as histology and/or
mutation status seemed to be more important than clinical
factors such as gender or smoking status.31
This study has some limitations. One is that we did not
know performance status of all subjects because this study
was retrospective. Nevertheless, BMI and FEV1 reflect nutri-
tional status and respiratory function, respectively, both of
which comprise a large portion of performance status.19 Also,
undergoing chemotherapy indirectly means acceptable per-
formance status.
In conclusion, reduced FEV1 (50% predicted) is
strongly associated with mortality in patients with advanced
NSCLC regardless of clinical stage. Also, this study showed
that chemotherapy and histology of adenocarcinoma are good
prognostic factors, whereas low BMI and the presence of
malignant pleural effusion predict short survival. Pretreat-
ment spirometry in advanced NSCLC and in resectable
NSCLC may assist in determining the optimal management
plan and allow for more accurate prediction of prognosis.
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